Cargando…

Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell lymphoma by modulating natural killer cells

BACKGROUND: The treatment of high‐risk B‐cell lymphoma (BCL) remains a challenge, especially in the elderly. METHODS: A total of 83 patients (median age 65 years), who have achieved a complete response after induction therapy, were divided into two groups: R(2) + GM‐CSF regimen (lenalidomide, rituxi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Shunrong, Fulati, Wulipan, Shen, Lin, Wu, Min, Huang, Zilan, Qian, Wensi, Chen, Pingping, Hu, Yingwei, Chen, Mingyue, Xu, Yu, Zhang, Hongdi, Ma, Jiexian, Xie, Yanhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315792/ https://www.ncbi.nlm.nih.gov/pubmed/37081754 http://dx.doi.org/10.1002/cam4.5969

Ejemplares similares

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study
por: Zhang, Yan, et al.
Publicado: (2021)

Pulmonary Alveolar Proteinosis Refractory to Plasmapheresis and Rituximab despite GM-CSF Antibody Reduction
por: Keske, Aysenur, et al.
Publicado: (2022)

GM-CSF in inflammation
por: Hamilton, John A.
Publicado: (2019)

G-CSF and GM-CSF in clinical trials.
por: Antman, K. H.
Publicado: (1990)

Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders
por: Lazarus, Hillard M., et al.
Publicado: (2023)

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018)

Role of GM-CSF in lung balance and disease
por: Chen, Yingzi, et al.
Publicado: (2023)

A role for G-CSF and GM-CSF in nonmyeloid cancers
por: Aliper, Alexander M, et al.
Publicado: (2014)

GM-CSF-Dependent Inflammatory Pathways
por: Hamilton, John A.
Publicado: (2019)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

Development of Dendritic Cells from GM-CSF(-/-) Mice in vitro : GM-CSF Enhances Production and Survival of Cells
por: Ni, Keping, et al.
Publicado: (2001)

Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis
por: Ma, Jiexian, et al.
Publicado: (2017)

Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF(+) T Lymphocytes
por: Bystrom, Jonas, et al.
Publicado: (2017)

Construction of Recombinant Human GM-CSF and GM-CSF-ApoA-I Fusion Protein and Evaluation of Their Biological Activity
por: Pykhtina, Mariya, et al.
Publicado: (2021)

Delivery of GM-CSF to Protect against Influenza Pneumonia
por: Subramaniam, Renuka, et al.
Publicado: (2015)

Pivotal Roles of GM-CSF in Autoimmunity and Inflammation
por: Shiomi, Aoi, et al.
Publicado: (2015)

A Review of GM-CSF Therapy in Sepsis
por: Mathias, Brittany, et al.
Publicado: (2015)

The efficacy and safety of targeting GM-CSF in arthritis
por: Bykerk, Vivian P
Publicado: (2020)

GM-CSF: Orchestrating the Pulmonary Response to Infection
por: McCormick, Thomas S., et al.
Publicado: (2022)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment
por: Bosteels, Cedric, et al.
Publicado: (2022)

Glutamine Deprivation Promotes the Generation and Mobilization of MDSCs by Enhancing Expression of G-CSF and GM-CSF
por: Sun, Hong-Wei, et al.
Publicado: (2021)

A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients with High/High-intermediate risk Diffuse Large B-Cell Lymphoma
por: Reddy, Nishitha M., et al.
Publicado: (2016)

GM-CSF facilitates the development of inflammation-associated colorectal carcinoma
por: Chen, Guojiang, et al.
Publicado: (2014)

G‐CSF/GM‐CSF‐induced hematopoietic dysregulation in the progression of solid tumors
por: He, Kai, et al.
Publicado: (2022)

GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma
por: Rong, Qi-xiang, et al.
Publicado: (2021)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
por: Zhang, Peng‐Fei, et al.
Publicado: (2020)

Determinants of a transcriptionally competent environment at the GM-CSF promoter
por: Brettingham-Moore, K. H., et al.
Publicado: (2008)

GM-CSF Primes Proinflammatory Monocyte Responses in Ankylosing Spondylitis
por: Shi, Hui, et al.
Publicado: (2020)

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)
por: Ho, Matthew, et al.
Publicado: (2021)

G-CSF and GM-CSF Modify Neutrophil Functions at Concentrations found in Cystic Fibrosis
por: Castellani, Stefano, et al.
Publicado: (2019)

Functional characterization of GM-CSF induced monocyte subsets
por: Däbritz, J, et al.
Publicado: (2008)

GM-CSF as a therapeutic target in autoimmune diseases
por: Shiomi, Aoi, et al.
Publicado: (2016)

Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update
por: Lotfi, Noushin, et al.
Publicado: (2019)

GM-CSF: A Promising Target in Inflammation and Autoimmunity
por: Lee, Kevin M C, et al.
Publicado: (2020)

GM-CSF - an oncogenic driver of HER2+ breast leptomeningeal metastasis
por: Garg, Rachana, et al.
Publicado: (2022)

P978: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR PATIENTS WITH MULTIPLE MYELOMA: INTERIM ANALYSIS OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA
por: Zhuang, Z., et al.
Publicado: (2022)

P873: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: UPDATE OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA
por: Zhuang, Zhe, et al.
Publicado: (2023)

GM-CSF Dependent Differential Control of Mycobacterium tuberculosis Infection in Human and Mouse Macrophages: Is Macrophage Source of GM-CSF Critical to Tuberculosis Immunity?
por: Mishra, Abhishek, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ss3l3da8aucuc390i0c1r29k93